Integrative deep learning strategies to enhance early-stage drug discovery: optimizing computational structure–activity modeling for pharmacotherapeutic innovation

TL;DR

This paper presents a deep learning framework that improves early drug discovery by accurately predicting analgesic compound activity with high precision.

Contribution

An optimized neural network framework with high predictive accuracy for analgesic compounds, outperforming conventional methods.

Findings

The optimized neural network achieved a 95.9% correlation coefficient and 0.433% prediction error.

Key descriptors like connectivity and polarity parameters were linked to analgesic activity, enhancing model interpretability.

The framework supports efficient computational screening and candidate prioritization for drug discovery.

Abstract

The integration of computational intelligence into therapeutic development is increasingly important for accelerating early-stage drug discovery and improving compound prioritization. In this study, we developed an optimized neural network–based predictive framework to support the identification of bioactive compounds with analgesic potential. A dataset of 532 structurally diverse molecules described by 227 molecular descriptors was analyzed, and a stepwise feature elimination procedure reduced the descriptor set to 105 informative variables, improving model robustness and reducing redundancy. The optimized artificial neural network, trained using the Levenberg–Marquardt algorithm, achieved a correlation coefficient of 95.9% with a prediction error of 0.433%, outperforming conventional statistical approaches reported for comparable QSAR tasks. Additional analysis links key descriptor groups, including connectivity and polarity parameters, to physicochemical properties relevant to analgesic activity, improving interpretability for medicinal chemistry applications. The framework is intended to support computational screening and candidate prioritization prior to experimental validation, thereby contributing to more efficient pharmacotherapeutic discovery workflows. This work highlights how data-driven modeling can complement translational strategies aimed at accelerating drug discovery pipelines.

Graphic showing a molecular structure feeding into a neural network model, which predicts therapeutic activity such as analgesic effects with 96 percent correlation, highlighting that deep learning outperforms conventional methods.

Figures